Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
about
Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repairRapalogs in cancer prevention: anti-aging or anticancer?Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild-type and BK5.AktWT mice.A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling.Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinomaREDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoidsRapamycin and mTORC1 inhibition in the mouse: skin cancer prevention.Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumorsPrevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damageA weighty problem: metabolic perturbations and the obesity-cancer link.Effect of Combined Treatment with Ursolic Acid and Resveratrol on Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate.p53 and rapamycin are additive.Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway.Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival.Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceEvaluation of pentacyclic triterpenes found in Perilla frutescens for inhibition of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.Obesity, energy balance, and cancer: new opportunities for preventionMetformin inhibits skin tumor promotion in overweight and obese mice.Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation.Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions.mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model.Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells.Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application.Immunosuppressants in cancer prevention and therapyWhile reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts.Translating Mechanism-Based Strategies to Break the Obesity-Cancer Link: A Narrative Review.Dietary energy balance modulation of epithelial carcinogenesis: a role for IGF-1 receptor signaling and crosstalk.
P2860
Q26822549-3B9A7F17-8558-4EA5-B443-098A939FC037Q26866151-095966AF-85B3-4E84-8F9D-5ACC1D9D6149Q33707315-B424FFDC-5DCF-444D-B314-B26B809C24BBQ34071264-ABF68056-0080-4C39-B535-C7BC69D6AAF3Q34184286-FE7F9382-3FF0-46A1-A38F-D4F99AAD27CDQ35023858-A7949F3F-5598-4EBA-B4A2-780579A923E3Q35106935-62BDF423-A38D-40AE-B256-25199CA8D8A4Q35149607-D867894E-A5F7-4273-8F00-B6E45166879DQ35356038-2FBB73D9-39A3-4603-8E72-11194D6AB665Q35563024-69FAC51F-5C04-4AFF-B1EB-7E9E932D84D6Q35689545-34A489F5-F3EF-49CE-BC78-C15FF54B1935Q36029673-71CB2E6B-2D67-4E5E-98CB-293BFE0DE720Q36140629-2F4F8F85-D2B8-4633-83EF-88A3F4DE4F69Q36334079-B713094A-56F0-45FA-8385-567BB408BBB7Q36456697-62916A9E-A07E-4781-8BAB-AC6B80886CFFQ36530674-FB80CF23-35B0-4B56-82BF-0793E1C65F52Q36544718-D54495B4-A495-417E-ABD1-548094AD0C31Q36629583-14299224-692B-40FD-A2E6-A8CD9335C437Q36649878-D3916A54-DC6D-4137-B5CC-2736FBE40D0BQ36810924-D1356562-2B17-4839-8DB0-7FC8F676182AQ37570847-6F65C394-6191-4F95-8049-56918826E0EBQ38187197-47CEDAB7-F707-4D6B-8E31-462F4EFAF01BQ38779851-5D74FFD1-EEB8-4702-A829-19119896E4B8Q38966698-44647589-983E-47E1-BBBE-807FA1372A05Q39623358-08E4BB90-ABB5-4C2A-8385-E5458B7D83D8Q40570781-06FBD314-5E94-43F5-921D-376E3398590AQ40604193-36643F20-9D88-4BD1-A67D-740906F938CBQ41020029-2C69539F-CA05-4FBC-AFDD-ABD91692F66CQ41628905-26767D85-AA6B-4B3A-BD03-4C9B743F27E0Q42505783-47462DC4-1B67-4CFA-9090-2BE587275AE2Q49713212-D64ED792-4132-43D8-BEEE-7CD9FF783BEFQ50162842-C95A27C8-0C4C-4161-BD01-69957635C7CDQ54571481-828EE084-C621-4288-B4C0-F8037C91430C
P2860
Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Rapamycin is a potent inhibito ...... tradecanoylphorbol-13-acetate.
@ast
Rapamycin is a potent inhibito ...... tradecanoylphorbol-13-acetate.
@en
type
label
Rapamycin is a potent inhibito ...... tradecanoylphorbol-13-acetate.
@ast
Rapamycin is a potent inhibito ...... tradecanoylphorbol-13-acetate.
@en
prefLabel
Rapamycin is a potent inhibito ...... tradecanoylphorbol-13-acetate.
@ast
Rapamycin is a potent inhibito ...... tradecanoylphorbol-13-acetate.
@en
P2093
P2860
P1476
Rapamycin is a potent inhibito ...... tradecanoylphorbol-13-acetate.
@en
P2093
John DiGiovanni
L Allyson Checkley
Okkyung Rho
Steve Hursting
Tricia Moore
P2860
P304
P356
10.1158/1940-6207.CAPR-10-0375
P577
2011-07-01T00:00:00Z